Binds Receptor Patents (Class 424/143.1)
  • Patent number: 10398764
    Abstract: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: September 3, 2019
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
  • Patent number: 10370449
    Abstract: The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 6, 2019
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Neil Graham, Marius Ardeleanu, Allen Radin, Jennifer D. Hamilton, Ariel Teper
  • Patent number: 10253107
    Abstract: The present invention relates to the use of endocytosis inhibitors, including clathrin-dependent endocytosis inhibitors such as inhibitors of dynamin and antibodies, for enhancing the immune response to cancer, and thereby treating cancers including cancer associated receptor positive cancers.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: April 9, 2019
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Fiona Simpson, Nicholas Andrew Saunders
  • Patent number: 10241118
    Abstract: The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 26, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Frances Balkwill, Chiara Berlato, Laura Fletcher
  • Patent number: 10231959
    Abstract: Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: March 19, 2019
    Inventor: Louis Habash
  • Patent number: 10221246
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 5, 2019
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Patent number: 10206990
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 19, 2019
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 10184005
    Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 22, 2019
    Assignee: MORPHOSYS AG
    Inventors: Michael Tesar, Ute Jaeger
  • Patent number: 10125195
    Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Roberto Depaz, Natalie DeJesus, Jared Bee
  • Patent number: 10087252
    Abstract: The present invention provides compositions and methods for treating and preventing disease associated with ?v?5 integrin by blocking binding to ?v?5 integrin. In particular, antibodies specific for ?v?5 integrin are useful for preventing, treating, and reversing sepsis.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 2, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dean Sheppard, George Su, Amha Atakilit
  • Patent number: 10071166
    Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 11, 2018
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Young Min Kim, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10039826
    Abstract: The current invention relates to a new pharmaceutical formulation, in particular to a pharmaceutical formulation comprising a protein, more particularly an antibody as an active ingredient.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 7, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Michael Joseph Edouard Boonen, Claude Peerboom
  • Patent number: 9937166
    Abstract: The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 10, 2018
    Assignee: Inflammatory Response Research, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 9927444
    Abstract: Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and/or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 27, 2018
    Assignee: Cornell University
    Inventors: Linda Vahdat, Shahin Rafii, Rakhi Naik, Maureen Lane, Vivek Mittal
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9867862
    Abstract: The present invention provides compounds and methods for the treatment of an individual having or at risk of having a condition associated with alpha-1-antitrypsin by using a pharmacological chaperone. In particular, such methods are useful for the treatment and/or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. The present invention also provides an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 16, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Eric Richard Sjoberg, Gary Lee
  • Patent number: 9789105
    Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 17, 2017
    Assignee: LOCL PHARMA, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 9777057
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ONCONOX APS
    Inventors: Francesco Tedesco, Pier Luigi Meroni, Daniele Sblattero
  • Patent number: 9772324
    Abstract: The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: September 26, 2017
    Assignee: Korea University Research and Business Foundation
    Inventor: Jae-Hong Kim
  • Patent number: 9718868
    Abstract: Described herein is insulin, an insulin-like growth factor, parathyroid hormone, a fragment of parathyroid hormone, or a parathyroid hormone related protein that includes at least one bone targeting moiety, wherein the bone targeting moiety is covalently bonded to the peptide. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and preventing bone fractures, and/or the inability to initiate de novo bone turnover and stimulate bone fracture repair.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: August 1, 2017
    Assignee: The Governors of the University of Alberta
    Inventors: Michael Doschak, Yang Yang, Krishna Hari Bhandari
  • Patent number: 9700594
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: July 11, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Makoto Kakitani, Kazuma Tomizuka
  • Patent number: 9688749
    Abstract: Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: June 27, 2017
    Assignee: AbbVie Inc.
    Inventors: Flaminia Pavone, Sara Martinelli, Antonino Cattaneo, Gabriele Ugolini
  • Patent number: 9663583
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 30, 2017
    Assignee: INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH
    Inventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz
  • Patent number: 9644035
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 9, 2017
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
  • Patent number: 9637542
    Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alisa K. Waterman, Nick Mark Devoogdt, Tony Lahoutte, Matthias Schneider, Sanjaya Singh, Cedric Jozef Néotère Ververken
  • Patent number: 9586914
    Abstract: Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: March 7, 2017
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: David Fairlie, Robert C. Reid
  • Patent number: 9562090
    Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: February 7, 2017
    Assignee: Domantis Limited
    Inventors: Laurent Jespers, Malgorzata Pupecka, Carolyn Enever, Ian Tomlinson
  • Patent number: 9562101
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: February 7, 2017
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Patent number: 9555107
    Abstract: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: January 31, 2017
    Assignee: Genentech, Inc.
    Inventors: Yvonne M. Chen, Anan Chuntharapai, Dimitry Danilenko, Wenjun Ouyang, Susan Sa, Patricia Valdez, Terence Wong, Jianfeng Wu, Yan Zheng
  • Patent number: 9555110
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: January 31, 2017
    Assignee: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • Patent number: 9545086
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: January 17, 2017
    Assignee: Biogen MA Inc.
    Inventors: Fabienne MacKay, Susan Kalled
  • Patent number: 9535055
    Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: January 3, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bo Gyou Kim, Kyung Ah Kim
  • Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • Patent number: 9505826
    Abstract: The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 29, 2016
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David Wilson, Tetsuya Taura
  • Patent number: 9499628
    Abstract: In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71+ cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71+ cells in the subject.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: November 22, 2016
    Assignee: Children's Hospital Medical Center
    Inventor: Sing Sing Way
  • Patent number: 9487579
    Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: November 8, 2016
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF MARYLAND, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
  • Patent number: 9453077
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: September 27, 2016
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Patent number: 9422369
    Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: August 23, 2016
    Assignee: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
  • Patent number: 9403910
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 2, 2016
    Assignees: Acceleron Pharma Inc., Dyax Corporation
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • Patent number: 9364535
    Abstract: Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a second antagonist for an integrin receptor. In some embodiments, the methods include enhancing survival of transplanted tissue in a subject. Aspects of the invention further include compositions, e.g., pharmaceutical compositions and kits that find use in methods of the invention.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 14, 2016
    Assignee: The Regents of the University of California
    Inventor: Lu Chen
  • Patent number: 9360484
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 7, 2016
    Assignee: GENENTECH, INC.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Patent number: 9295722
    Abstract: Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: March 29, 2016
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, THE UNIVERSITY OF CHICAGO, BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Albert Bendelac, Luc Teyton
  • Patent number: 9284369
    Abstract: The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Napoleon Ferrara, Farbod Shojaei, Xiumin Wu, Cuiling Zhong
  • Patent number: 9249228
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 2, 2016
    Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Patent number: 9226972
    Abstract: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: January 5, 2016
    Assignee: Auburn University
    Inventors: Valery A. Petrenko, Deepa Bedi, Olusegun A. Fagbohun, James W. Gillespie
  • Patent number: 9221910
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 29, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Patent number: 9206256
    Abstract: The present invention relates to DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The present invention further provides methods of using agents that modulate the activity of DDR1, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 8, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • Patent number: 9193790
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: November 24, 2015
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony Fauci
  • Patent number: 9193791
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: November 24, 2015
    Assignee: City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery
  • Patent number: 9175062
    Abstract: The present disclosure provides a method for recombinant production of human sRAGE in mammalian cells, as well as a human sRAGE having a mammalian post-translational modification and compositions thereof. The present disclosure also provides a method of treating a vascular disease, injury, or inflammation in a mammal by administering to a mammal with a vascular disease, injury, or inflammation a composition comprising human sRAGE having a mammalian post-translational modification, thereby treating the vascular disease, injury, or inflammation in the mammal.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: November 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Li Lin, Sungha Park, Wen Wei, Rui-Ping Xiao, Mark I. Talan, Edward G. Lakatta